Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer
2017 ◽
2017 ◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. 509-509
◽
2020 ◽
Vol 46
(6)
◽
pp. e48-e49